United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. raised its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 862.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,877 shares of the biotechnology company’s stock after purchasing an additional 1,682 shares during the period. TD Waterhouse Canada Inc.’s holdings in United Therapeutics were worth $662,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in UTHR. Signaturefd LLC raised its position in United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after acquiring an additional 30 shares during the period. Parallel Advisors LLC increased its stake in shares of United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 30 shares in the last quarter. Anchor Investment Management LLC raised its position in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 30 shares during the last quarter. Great Lakes Advisors LLC lifted its stake in United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after buying an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its holdings in United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In related news, Director Raymond Dwek sold 3,000 shares of the business’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $285.57, for a total value of $856,710.00. Following the sale, the director now owns 1,750 shares in the company, valued at approximately $499,747.50. The trade was a 63.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $911,330.28. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 84,500 shares of company stock worth $28,179,150. Insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on UTHR. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 17th. HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Bank of America upgraded shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target on the stock in a research report on Monday, April 21st. Finally, JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $357.00 to $355.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $390.17.

United Therapeutics Stock Down 1.7 %

NASDAQ:UTHR opened at $291.38 on Friday. The company has a market capitalization of $13.09 billion, a P/E ratio of 12.80, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 52 week low of $233.31 and a 52 week high of $417.82. The stock’s fifty day moving average is $308.67 and its two-hundred day moving average is $346.55.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same quarter in the prior year, the company posted $4.36 earnings per share. Sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.